Survival benefits of chemotherapy for unresectable biliary tract cancer - A multicenter retrospective analysis

Akihiro Funakoshi, Hikoyuki Horiuchi, Terufumi Sakai, Toshihiko Miyahara, Toru Muranaka, Masashi Nakamura, Kazuhiro Mizumoto, Toshiharu Ueki, Akinobu Taketomi, Hiroya Yamaguchi, Toshihiko Sumii, Tetsuhide Ito

Research output: Contribution to journalArticlepeer-review

Abstract

There is no agreement on the standard chemotherapeutic regimen for biliary tract cancer (BTC), although multi-drug regimens such as gemcitabine and/or S-1 have been tested in clinical trials. This study retrospectively reviewed data from patients with BTC who were seen at hospitals in the Kitakyushu and Fukuoka areas between 2005 and 2006, and examined the effect of systemic chemotherapy regimen on survival benefits in patients with unresectable BTC. Chemotherapy may benefit patients with BTC any age group, regardless of the primary site.

Original languageEnglish
Pages (from-to)2875-2879
Number of pages5
JournalJapanese Journal of Cancer and Chemotherapy
Volume37
Issue number13
Publication statusPublished - Dec 2010

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Survival benefits of chemotherapy for unresectable biliary tract cancer - A multicenter retrospective analysis'. Together they form a unique fingerprint.

Cite this